Ozanimod is an approved treatment for relapsing forms of multiple sclerosis. This article summarizes the latest clinical trial data shared at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the 32nd Annual Meeting of the European Charcot Foundation.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given